| 12/31/2008 | SS | Alpharma shareholder Gamco rescinds proposal in light of King Pharmaceuticals' offer
|
| 12/31/2008 | SS | King Pharmaceuticals acquires Alpharma for $37 per share
|
| 12/24/2008 | SS | Market Commentary: Johnson & Johnson tender offer for Omrix expires Friday; Emageon buyout lacks financing
|
| 12/22/2008 | SS | King extends tender offer for Alpharma to Dec. 29
|
| 12/22/2008 | SS | Market Commentary: Johnson & Johnson, King Pharma buyouts considered done deals; InfoGroup founder explores sale
|
| 12/11/2008 | SS | Wells Fargo trims stake to less than 5% in Alpharma
|
| 11/25/2008 | SS | Market Commentary: Rio Tinto falls after BHP backs out; Exelon forges ahead with NRG bid; PNM clears step in gas sale
|
| 11/24/2008 | CV | Market Commentary: Citigroup jumps on government rescue; B of A, Wachovia rise; Alpharma little changed on merger news
|
| 11/24/2008 | SS | King Pharmaceuticals, Alpharma agree to combine
|
| 11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
| 10/16/2008 | SS | Deerfield Capital reports 6.18% passive stake in Alpharma
|
| 10/13/2008 | SS | King Pharmaceuticals' offer for Alpharma extended to Nov. 21
|
| 10/8/2008 | SS | Gabelli, Gamco purchase 478,500 Alpharma shares for 9.5% stake
|
| 10/6/2008 | SS | King Pharmaceuticals, Alpharma announce confidentiality agreement
|
| 10/6/2008 | SS | Market Commentary: Wachovia war hits the courts but short truce declared; International Rectifier rebuffs Vishay
|
| 9/29/2008 | SS | FTC wants more information about proposed merger of King Pharmaceuticals, Alpharma
|
| 9/29/2008 | SS | Market Commentary: Wachovia plummets on banking-asset sale; ImClone, Alpharma savor mystery suitors
|
| 9/26/2008 | SS | Market Commentary: WaMu nosedives on U.S. seizure, industry wonders who's next; Alpharma says other offer tops King;
|
| 9/26/2008 | BK | Market Commentary: Fresenius Kabi widens OID, breaks for trading; Cash sees shortage of buyers; LCDX holds steady
|
| 9/26/2008 | SS | Alpharma continues to reject King's offer, enters into confidentiality agreements with other parties
|
| 9/25/2008 | SS | Companies may benefit from new leadership, Gamco Investors says
|
| 9/24/2008 | SS | Gamco could seek individuals to join boards of numerous public companies
|
| 9/24/2008 | SS | Gabelli continues to buy shares of Alpharma
|
| 9/19/2008 | SS | Gabelli buys 393,800 shares of Alpharma for 8.42% stake
|
| 9/17/2008 | SS | Gabelli continues to invest in Alpharma, reports 7.38% interest
|
| 9/12/2008 | SS | King Pharmaceuticals begins tender offer for Alpharma
|
| 9/12/2008 | SS | Market Commentary: Lehman, WaMu stutter along; King tenders for Alpharma; Longs holders shun CVS as Walgreen steps in
|
| 9/11/2008 | SS | King Pharmaceuticals to begin $37-per-share cash tender offer for Alpharma
|
| 9/10/2008 | SS | Gabelli ups stake in Alpharma to 5.54%
|
| 9/2/2008 | SS | Alpharma adopts rights plan, amends change-in-control plan
|
| 9/2/2008 | SS | Market Commentary: Lehman gyrates as KDB may take stake; Alpharma prescribes poison pill
|
| 8/26/2008 | SS | Gabelli, Gamco report 5.05% stake in Alpharma
|
| 8/22/2008 | SS | King Pharmaceuticals makes public its $33-per-share offer for Alpharma
|
| 8/22/2008 | SS | Market Commentary: King reveals nixed bid for Alpharma; Genentech will pay to keep staff; Sovereign gyrates on GSE fears
|
| 8/22/2008 | CV | Market Commentary: Lehman jumps on speculation; King holds, Alpharma up on takeover bid; China Sunergy up on earnings
|
| 6/25/2008 | BKCVHY | Alpharma says cash slated for possible share repurchases, growth opportunities
|
| 2/20/2008 | BKCVHY | Alpharma says recent divestiture opened door to opportunities within remaining business segments
|
| 5/31/2007 | CVHY | Alpharma shifting focus toward growing revenues by making operational investments
|
| 3/23/2007 | BKCVHY | S&P rates Alpharma, convertibles B+
|
| 3/16/2007 | CV | Market Commentary: Alpharma improves in trading start; JetBlue gains amid flight cancellations; Michelin prices deal
|
| 3/15/2007 | CV | New Issue: Alpharma prices upsized $300 million of 20-year convertibles at rich end, at 2.125%, up 35%
|
| 3/15/2007 | CV | Market Commentary: Stanley Works sprints off the blocks; Amgen retreats on Medicare review; Alpharma bright in gray market
|
| 3/15/2007 | CVHY | Alpharma files automatic shelf registration
|
| 9/29/2006 | BT | Alpharma: phase 2 results show anti-abuse properties of extended-release opioid
|
| 7/31/2006 | BT | Alpharma second-quarter earnings up, revenues rise 16% for the period
|
| 7/7/2006 | BKBTHY | S&P ups Alpharma
|
| 5/4/2006 | BT | Alpharma says Kadian capsules effective for arthritis, fibromyalgia patients
|
| 5/1/2006 | BT | Alpharma says Q1 EPS more than triples to $0.62, revenue hits $34.9 million
|
| 3/14/2006 | BKBT | Alpharma gets $75 million amended and restated revolver
|
| 3/8/2006 | BT | Alpharma to sell telemarketing business for $40.1 million
|
| 12/23/2005 | BTCVHY | Alpharma to redeem 8 5/8% notes, 3% convertibles
|
| 12/13/2005 | BKBT | Alpharma gets $95 million revolver
|
| 12/8/2005 | BT | Alpharma receives tentative FDA approval for generic Zoloft
|
| 11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
| 11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
| 10/28/2005 | BKBTCVHY | Moody's affirms Alpharma
|
| 10/27/2005 | BKBT | Alpharma gets $210 million credit facility
|
| 10/21/2005 | BKBTCVHY | S&P ups Alpharma outlook to stable
|
| 10/17/2005 | BT | Alpharma announces sale of generics businesses to Actavis
|
| 8/29/2005 | BT | Market Commentary: AtheroGenics, Amylin Pharma, Alpharma extend gains on takeover chatter; Pfizer, Merck credit mixed
|
| 8/22/2005 | BT | Market Commentary: Alpharma gains on deal chatter; OSI plunges, Eyetech up on deal; QLT higher; Acambis slides
|
| 7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
| 7/19/2005 | BT | S&P: U.S. generic drug industry entering more challenging period; Alpharma, Mylan, Teva, Watson at risk
|
| 4/13/2005 | BKCVHY | Moody's affirms Alpharma
|
| 3/31/2005 | CV | Alpharma to cut 6.875% convertibles to $10 million by Dec. 1
|
| 3/11/2005 | BK | Alpharma amends loan to extend reporting deadline, gain room under covenants
|
| 10/12/2004 | BKHY | S&P: Alpharma unaffected
|
| 10/11/2004 | CV | S&P: Alpharma unaffected
|
| 10/11/2004 | CV | Market Commentary: Northwest, Delta lead lower on fuel prices, pilot contract concerns; drug paper higher
|
| 8/18/2004 | BKCVHY | S&P: Alpharma unaffected
|
| 8/9/2004 | BKDDHY | S&P cuts Alpharma ratings
|
| 6/3/2004 | BKCVHY | Moody's upgrades Alpharma
|
| 11/19/2003 | BKCVHY | S&P cuts Alpharma ratings
|
| 11/14/2003 | BKCV | Alpharma might exchange convertibles for stock, amend bank covenants
|
| 9/9/2003 | CV | Market Commentary: Cummins gains as buyers step in; Alpharma deeply wounded by lower guidance; telecoms slide
|
| 8/19/2003 | BK | Market Commentary: Secondary sees strong bidding interest ahead of Labor Day lull, pushing some names higher
|
| 4/16/2003 | HY | Market Commentary: Equistar prices upsized $450 million; Levi descends more, Better Minerals soars on sale of unit
|
| 4/16/2003 | BKCVHY | Moody's rates CMS bank facilities B2
|
| 4/16/2003 | HY | New Issue: Alpharma prices upsized $220 million eight-year notes to yield 8 5/8%
|
| 4/15/2003 | HY | Alpharma eight-year notes upsized to $220 million, talked at 83/4%-9%
|
| 4/15/2003 | HY | Market Commentary: Four deals price as market stays hot; Levi Strauss plunges on tax allegations, Charter up
|
| 4/8/2003 | HY | Alpharma starts roadshow for $200 million seven-year notes
|
| 4/8/2003 | HY | Market Commentary: Market mostly range-bound, though airlines, power off; Park Place split-rated deal prices
|
| 2/26/2003 | BK | Moody's raises Alpharma outlook
|
| 2/26/2003 | CV | Moody's ups Alpharma outlook
|
| 2/26/2003 | HY | Moody's upgrades Chesapeake, rates notes Ba3, converts B3
|
| 2/18/2003 | CV | S&P confirms Alpharma
|
| 2/18/2003 | HY | Moody's raises BSkyB outlook
|
| 2/18/2003 | BK | Moody's raises BSkyB outlook
|
| 1/10/2003 | CV | Market Commentary: Motley trading, mostly up; State Street launches deal
|
| 1/9/2003 | BK | Alpharma intends to reduce debt in 2003 with free cash flow
|
| 9/3/2002 | CV | Moody's cuts Aquila to junk
|
| 9/3/2002 | HY | Moody's cuts Aquila to junk
|
| 9/3/2002 | BK | Moody's cuts Aquila to junk
|
| 9/3/2002 | BK | Market Commentary: Alpharma shrugs off downgrade, bid/ask stays wide; Wyndham unmoved by debt cut
|
| 8/22/2002 | BK | Market Commentary: Cable names rebound as stocks continue to improve
|
| 7/30/2002 | BK | Fitch lowers Williams Cos.
|
| 7/30/2002 | CV | S&P cuts Orbital convertible to CCC-
|
| 7/30/2002 | HY | Fitch lowers Williams Cos.
|
| 7/3/2002 | CV | Fitch rates Mirant at BBB-
|
| 7/3/2002 | HY | Moody's puts Qwest on review
|
| 6/10/2002 | BK | Moody's puts Riverwood's ratings on review
|
| 6/10/2002 | CV | Fitch cuts Tyco ratings to junk
|
| 6/10/2002 | HY | Moody's puts Riverwood's ratings on review
|
| 4/10/2002 | CV | Deutsche analysts say credit work provides insight for generic drug picks
|
| 3/21/2002 | CV | Alpharma to exchange further $70 million of convertibles for stock
|
| 3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
| 3/14/2002 | CV | Alpharma exchanges $40 million convertibles for stock
|
| 3/8/2002 | CV | Market Commentary: Convertibles gain on Nasdaq strength; Alpharma drops
|
| 12/31/2001 | CV | Alpharma exchanges further $17 million convertibles
|
| 12/24/2001 | CV | Alpharma exchanges $17 million convertibles, may exchange more
|
